Table 1.
Study | Country | Age range | Male n (%) | Study design | Total pt # | # of SS | # of controls | Scoring system | +score of US | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
pSS | sSS | sSS | Sicca | HC | ||||||||
El Miedany et al.10 | Egypt | 47–66 | 9 (19%) | cross-sectional cohort | 87 | 47 | 20 | 20 | 0–3 | ≥1 | ||
Niemela et al.11 | Finland | 18–67 | 1 (4%) | cross-sectional cohort | 81 | 27 | 27 | 27 | 0–4 | ≥1 | ||
Su et al.12 | China | 44–64 | not specified | case-control | 63 | 28 | 5 | 30 | 0–4 | ≥1 | ||
Hocevar et al.13 | Slovenia | not specified | not specified | prospective cohort | 218 | 68 | 150 | 0–48 | ≥17 | |||
Yang et al.14 | China | 20–58 | not specified | retrospecctive study | 41 | 41 | 0–4 | ≥2 | ||||
Song et al.15 | China | 26–65 | 12 (12%) | case-control | 128 | 98 | 30 | 0–4 | ≥1 | |||
Salaffi et al.16 | Italy | 30–78 | 3 (4%) | prospective cohort | 156 | 77 | 79 | 0–16 | ≥6 | |||
Poul et al.17 | UK | 20–85 | 5 (14%) | prospective cohort | 60 | 36 | 9 | 15 | unknown | |||
Milic et al.18 | Serbia | 21–78 | 4 (4%) | prospective cohort | 135 | 107 | 28 | 0–48 | ≥19 | |||
Milic et al.19 | Serbia | 21–78 | 6 (5%) | prospective cohort | 245 | 115 | 44 | 50 | 36 | 0–12 | ≥6 | |
Xu et al.20 | China | 28–78 | 0 (0%) | case-control | 103 | 44 | 27 | 32 | 0–16 | ≥8 | ||
Takagi et al.21 | Japan | 56 ± 13 | 20 (11%) | prospective cohort | 360 | 134 | 54 | 172 | 0–4 | ≥1 | ||
Kong et al.22 | China | 27–63 | 6 (11%) | case-control | 84 | 15 | 39 | 30 | 0–48 | unknown | ||
Milic et al.23 | Serbia | 21–78 | 10 (7%) | prospective cohort | 190 | 140 | 50 | 0–16 | ≥7 | |||
Cornec et al.24 | France | 56.8 ± 12.7 | 7 (9%) | prospective cohort | 158 | 78 | 80 | 0–4 | ≥2 | |||
Theander et al.25 | Sweden | 20–91 | not specified | cross-sectional cohort | 162 | 105 | 6 | 19 | 32 | 0–3 | ≥2 | |
Hammenfors et al.26 | Norway | not specified | 6 (6%) | cross-sectional cohort | 97 | 97 | 0–3 | ≥2 | ||||
Baldini et al.27 | Italy | 47 ± 13 | 2 (4%) | cross-sectional cohort | 107 | 50 | 57 | 0–3 | ≥2 | |||
Zhang et al.28 | China | 56.42 ± 10.21 | 4 (4%) | prospective cohort | 162 | 105 | 41 | 16 | 0–16 | ≥7 | ||
0–48 | ≥15 | |||||||||||
Lin et al.29 | China | 46.3 ± 13.1 | 6 (14) | prospective cohort | 94 | 44 | 14 | 36 | 0–12 | ≥6 | ||
0–16 | ≥6 | |||||||||||
0–48 | ≥17 | |||||||||||
Zhou et al.30 | China | 32–80 | 1 (2%) | case-control | 85 | 53 | 32 | 0–4 | ≥2 | |||
Zhou et al.31 | China | 32–82 | 2 (3%) | case-control | 165 | 71 | 45 | 49 | 0–4 | ≥2 | ||
Chen et al.32 | China | 23–77 | 1 (2%) | cross-sectional cohort | 136 | 51 | 35 | 50 | 0–3 | ≥1 | ||
Qi et al.33 | China | 49.75 ± 15.52 | 8 (6%) | retrospective cohort | 243 | 134 | 109 | 0–3 | ≥2 | |||
0–16 | ≥5 |
PSS = primary Sjögren’s syndrome; pt = patient; sSS = second Sjögren’s syndrome; HC = healthy control; US = ultrasonography.